Risk factors for developing depressive symptoms in the immediate postoperative period after Mohs micrographic surgery

ABSTRACT

Purpose

Mohs micrographic surgery (MMS) is a highly efficacious, tissue sparing method of skin cancer removal. Nevertheless, in the months to years after MMS, psychosocial distress has been described. The present study addressed the immediate period after MMS and assessed the frequency and risk factors for development of depressive symptoms.

Methods

Subjects undergoing MMS at two physician practices (JL, FS) were included in this prospective cohort study. Preoperatively, a standardized depression screening, the Patient Health Questionnaire-8 (PHQ-8), was administered. After MMS, the PHQ-8 was readministered at weeks 1, 2, 4, 6, and 12. Average PHQ-8 score by week and change from baseline PHQ-8 score were the primary outcomes.

Results

Sixty-three subjects were included of which 49 (78%) had a facial site. Twenty-two subjects (35%) had some increase in score during the 12-week follow-up period, of which 18 had a facial site. The oldest subjects (83–99 years, n = 14) had significantly higher PHQ-8 scores at week 4 (p < 0.01) and week 6 (p = 0.02) than all other age groups. There were no differences in scores between location groups.

Conclusions

One-third of subjects had some increase in score during the follow-up period. Those in the oldest age cohort were at highest risk of increased score. In contrast to prior literature, those with facial sites were not at higher risk. This difference may be explained by increased masking during the ongoing COVID-19 pandemic. Ultimately, consideration of patients’ psychologic status in the immediate postoperative period after MMS, particularly in the elderly population, may enhance perceived patient outcomes.

KEYWORDS:

• Mohs micrographic surgery
• skin cancer
• depression

Acknowledgment

Support with statistical analysis was received from Jimmy Duong, a Biostatistician at Columbia University Medical Center, New York, NY.

Proprietary interest statement

LG - Royalties from Thieme Medical Publishers. No other authors have proprietary interests to report.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

The Edward S. Harkness Eye Institute at Columbia University Irving Medical Center is supported by an unrestricted grant from Research to Prevent Blindness.